Perrigo stock is trading at US$10.72 after a long stretch of weak returns, and the valuation checks now suggest the market may be pricing the shares more cautiously than the fundamentals alone would indicate.

• Perrigo shareholders have seen the stock fall 71.3% over the past 5 years, which raises the question of whether expectations have simply moved too far the other way.
• For the valuation to hold up, the key support will come from Perrigo’s ability to convert its healthcare portfolio into steady cash flows. The main risk is that pressure on margins or execution causes those cash flows to lag what the current price assumes.
• Perrigo screens as undervalued on the broader checks, with the stock passing 6 of 6 valuation tests on Simply Wall St’s framework. You can see this in more detail at 6 out of 6.

The issue now is whether Perrigo’s current price already reflects the long period of weak returns, or if the valuation still builds in more caution than the business outlook warrants.

Is Perrigo a Bargain on Sales?

P/S is a useful anchor for Perrigo because the business is more often judged on its revenue base than on current earnings, which can be affected by one off items. On this measure, Perrigo trades on a P/S of about 0.4x, compared with an industry average of 6.2x and a peer group average of about 9.8x for Pharmaceuticals stocks.

The tailored fair P/S ratio for Perrigo is estimated at about 2.0x, which already factors in its sector, size and risk profile. The current multiple sits far below that fair level, suggesting the stock is priced at a heavy discount to what this framework would usually assign to a company with Perrigo’s revenue characteristics.

On the P/S multiple, Perrigo stock appears undervalued relative to both its industry and the modelled fair ratio.

The Perrigo Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Perrigo pick up where the valuation puzzle leaves off, spelling out which combinations of future growth, margins and earnings would need to apply for the stock to be worth materially more or less than today’s price. Rather than relying on a single multiple or model output, each narrative lays out the assumptions behind its view of fair value so you can compare those expectations with Perrigo's results as they are reported; they sit on Simply Wall St's Community page.

One of the top community narratives on Perrigo: 46% undervalued

"The company's highly disciplined approach to demand generation, combining advanced retail partnership models, targeted promotions, and data-driven household penetration initiatives, creates powerful network effects…"

Do you think there's more to the story for Perrigo? Head over to our Community to see what others are saying!

The Bottom Line

Perrigo looks undervalued on the market multiples used here, with the P/S gap to peers pointing to a cautious market stance relative to its revenue base. That discount only closes if Perrigo turns its healthcare portfolio into consistent cash flows without persistent margin or execution setbacks. For investors, the key question is whether the current low multiple reflects an overly pessimistic view or whether it is a fair response to the risk that cash generation falls short of what the present valuation quietly assumes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.